News
GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...
GSK PLC GSK shares dropped 2.45% to £15.12 Friday, on what proved to be an all-around poor trading session for the stock ...
GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...
GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...
2d
Pharmaceutical Technology on MSNBharat Biotech acquires licence for GSK’s Shigella vaccine developmentGSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for the continued development and ...
GSK RSV vaccine Arexvy accepted for regulatory review by EMA to expand use in adults 18 years, older
London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...
India also impacted by Shigellosis, a severe form of bacterial diarrhoea that disproportionately affects children under five ...
GSK has licensed its shigella vaccine candidate to Bharat Biotech. The Big Pharma, which has vowed to help Bharat with trial ...
This collaboration reflects Bharat Biotech’s continued commitment to global public health and equitable vaccine access ...
Under terms of the deal, Bharat Biotech will lead late-stage development and scale-up of the altSonflex1-2-3 Shigella vaccine ...
GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...
After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results